Key result
A single dose of recombinant factor VIIa (10-40 microg/kg) reduced INR to ≤1.5 within 10 minutes in all 7 patients with CNS bleeding on VKA therapy, and all patients survived.
Why the study?
Does recombinant factor VIIa reduce INR in patients with central nervous system bleeding during vitamin-K antagonist treatment?
Population
7 patients presenting with central nervous system bleeding emergencies during vitamin-K antagonist treatment…
Design
Case_series
Authors
Loading...
rFVIIa may aid refractory VKA bleeding reversal; single-case report leaves open need for controlled trials.
Case Report (n=7)
Does recombinant factor VIIa reduce INR in patients with central nervous system bleeding during vitamin-K antagonist treatment?
Recombinant factor VIIa rapidly and effectively reverses elevated INR in patients with VKA-associated CNS bleeding without apparent thromboembolic complications.
Sørensen et al. (2003) conducted a case report in Central nervous system bleeding during warfarin thromboprophylaxis (n=7). Recombinant activated factor VII (rFVIIa) was evaluated on Reduction of INR to <= 1.5 at 10 minutes. A single dose of recombinant factor VIIa (10-40 microg/kg) reduced INR to ≤1.5 within 10 minutes in all 7 patients with CNS bleeding on VKA therapy, and all patients survived.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: